Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial. - Wikidata - wikimedia - TriplyDB

Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial.

Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial.

http://www.wikidata.org/entity/Q33828657

about

Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malariaedit Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria Artemisinin combination therapy for vivax malaria Anti-malarial Drug Design by Targeting Apicoplasts: New Perspectives Antimalarial efficacy of piperaquine-based antimalarial combination therapies: facts and uncertainties Epidemiology and Control of Plasmodium vivax in Afghanistan Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium vivax malaria in endemic countries: meta-analysis of randomized controlled studies Dihydroartemisinin-piperaquine vs. artemether-lumefantrine for first-line treatment of uncomplicated malaria in African children: a cost-effectiveness analysis Geographical variation in Plasmodium vivax relapse Malaria: an update on current chemotherapy.Efficacy and safety of artemisinin combination therapy (ACT) for non-falciparum malaria: a systematic review.Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics.Cost-effectiveness of malaria diagnosis using rapid diagnostic tests compared to microscopy or clinical symptoms alone in Afghanistan.Substandard antimalarials available in Afghanistan: a case for assessing the quality of drugs in resource poor settings.Plasmodium vivax treatments: what are we looking for?Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum.Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico.In vivo Susceptibility of Plasmodium vivax to Chloroquine in Southeastern Iran.The global pipeline of new medicines for the control and elimination of malaria Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010.A Randomized Comparison of Chloroquine Versus Dihydroartemisinin-Piperaquine for the Treatment of Plasmodium vivax Infection in Vietnam.Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria.Prevalence and patterns of antifolate and chloroquine drug resistance markers in Plasmodium vivax across Pakistan.Immune response pattern in recurrent Plasmodium vivax malaria.Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated plasmodium falciparum malaria in Uganda.Management of relapsing Plasmodium vivax malaria Plasmodium vivax chloroquine resistance and anemia in the western Brazilian Amazon Therapeutic efficacy of chloroquine and primaquine for Plasmodium vivax malaria treatment in southeast Iran.Chloroquine-Primaquine versus Chloroquine Alone to Treat Vivax Malaria in Afghanistan: An Open Randomized Superiority Trial.[Plasmodium vivax malaria recurrence according to the use of primaquine: analysis of longitudinal descriptive studies].The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis

P2860

Q21032449-72E6BD3D-5773-4157-82A8-4B82B58D2A22 Q24202910-A8AB7D8C-7F4A-4BBF-93C8-93C55B24A48C Q24235351-D54B48A7-51E1-486B-81FC-384A4A29D220 Q24622539-87C93BA8-E137-4685-8889-17707B00C5DF Q26747361-70537173-6468-451A-8E36-D564A1CB4A27 Q26866187-7EBDED18-FA96-4290-BF59-E5D80BEF45C3 Q28355710-EF7884D5-1D2D-4D68-9F7F-B04054A43DD3 Q28535686-C6592710-3137-40CD-8065-661E86CD0DF2 Q28538065-584FF666-3F71-4D87-AC20-35A93C7B26F4 Q33613545-460A079B-620F-44F6-8C51-1FBDEF009455 Q34433106-19379267-D1D5-44A3-9EAB-946B08133003 Q34646141-88C418E6-0726-4AC8-8C09-54A34BD73F0D Q34699136-0E421872-E4CE-4839-884B-A6244DFB5E42 Q35669442-EFB35E90-EFC5-4744-9AE0-26B757D29F7E Q35681822-928766FD-B9AB-4DC7-9332-A25426D827EE Q35760893-E9B90387-E96A-4433-8BB1-4CCD2EDF2946 Q35834198-26B10E7D-5B08-4E3B-990A-543DECF3E81D Q36235143-4A742FB4-2B2E-47DD-B74A-7F9C19C31A1A Q36311473-BF674235-E832-4E35-93E1-81E4FDC946F0 Q36320249-00F0B89D-955E-434D-B9D2-9CE75B63460B Q36558557-C865DCE4-BD55-43A1-8D2B-39FA5029B38A Q36776130-97FA6145-DF28-4F1A-9343-F5A7B4658819 Q37077284-6557935D-8A28-484B-B658-69BFE48D9514 Q37155111-1AAFF36F-C774-4B04-A836-23BAC581CBFF Q37224228-E5C3FC06-EB47-4F93-BCBA-2523E049E913 Q37263818-BC708A55-4883-49C6-90AF-F7006482BA17 Q37290599-E69AFDC3-03F2-422F-B812-40045C8E7DF5 Q37544412-C02F81AD-0647-402C-8566-42EDF5A5D2A4 Q45787143-30C2E5A8-E3E1-47EB-A47A-F26887C4B24C Q48016667-5691BA14-829B-4DA7-9BC5-9330D3CBF404 Q48023392-27CCD0AD-F14D-4B9C-8F4D-D2B3C2902996 Q56338338-9EDAAE3F-28C4-44C6-95E7-BECAF5FAB5AD

P2860

Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial.

http://www.wikidata.org/entity/Q33828657

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Dihydroartemisinin-piperaquine ...... mized, non-inferiority, trial.

@ast

Dihydroartemisinin-piperaquine ...... mized, non-inferiority, trial.

@en

type

label

Dihydroartemisinin-piperaquine ...... mized, non-inferiority, trial.

@ast

Dihydroartemisinin-piperaquine ...... mized, non-inferiority, trial.

@en

prefLabel

Dihydroartemisinin-piperaquine ...... mized, non-inferiority, trial.

@ast

Dihydroartemisinin-piperaquine ...... mized, non-inferiority, trial.

@en

P1433

Q33828657-6323F5C9-BBBA-40E7-A5E6-8DD19EB87D85

P1476

Q33828657-B1574702-A3BC-4E77-9A03-EAC91E7FC4FC

P2093

Q33828657-84EA1996-3916-4C77-B781-4F8311EE16D1

Q33828657-97F10F97-8A54-467A-BDF5-ED205CBCF5C3

Q33828657-EF78B6AC-9754-41BB-ACAF-75E61DB1C8FA

Q33828657-FAE55CBB-251C-40C6-8AE8-5BA673DC8249

P2860

Q33828657-0CB916A7-34DD-4733-8E1A-44A2591BC08B

Q33828657-1833001F-FAAC-445A-B0E6-9FC28D386DF5

Q33828657-19E12C3B-35C6-4556-8329-FF88AE1D3827

Q33828657-1D1E08F6-9DCB-4E02-BA96-D7457010B0D1

Q33828657-2041CD70-0F13-4878-8E78-5D537A446A42

Q33828657-2154C96C-4028-408C-B7D2-E6BB55DB6248

Q33828657-26A63243-238E-4A9E-B6F2-CA45196650DD

Q33828657-26B2A05E-4451-4368-875D-70135AC9E7AF

Q33828657-29B8EF70-843C-4349-91A0-8F9F8EA4A442

Q33828657-2AF5CD4F-5EB2-4C24-ACEB-A7801EEDAC7A

P2888

Q33828657-6E4A4599-7C40-46EC-AFD0-230CB69F7041

P304

Q33828657-FB5ADD1D-C53E-4FC2-BC38-F4450A0765B2

P31

Q33828657-0727B2F7-430E-4EF7-90D3-F73637108504

P356

Q33828657-DD8E55B3-C5AC-4AD6-AA18-F7D3ACACEDAF

P478

Q33828657-A6053DC4-BFC6-412F-9505-05B3CA8EFAE4

P50

Q33828657-1C250BB0-B909-45D2-AFD4-0CDCFAD7AE7E

Q33828657-8450CA1B-E671-466A-B438-8DF2B84FFE2E

Q33828657-937CC2AC-8E5D-4206-B30F-04DA0AA5F45B

Q33828657-CF17CBBC-7CDD-4467-9B83-9CB3DD9C2EAF

Q33828657-D10A9EE4-A220-4502-9133-8141B34BAACD

Q33828657-E0915450-256B-407C-89B2-F4789AAFF45A

P577

Q33828657-319D0A3D-D639-45C8-B7EE-758F91F7B2B4

P5875

Q33828657-2F9DB809-355E-47D7-A7D0-9A836E7C1E4D

P6179

Q33828657-00248147-C1AC-44D5-83C2-A56160730A64

P698

Q33828657-DF510376-8020-45BD-9988-915B730794EF

P921

Q33828657-10BF9373-7E76-4CA0-B459-38208F02EE74

Q33828657-16C237AE-6D32-4F2F-B62C-32B10325C943

Q33828657-26DC859D-7B2B-4F4B-9286-4C77D9B5A16E

P932

Q33828657-2B2F39F6-B3F6-4110-883A-2EBB07A29998

P356

1475-2875-9-105

P1433

Malaria Journal

P1476

Dihydroartemisinin-piperaquine ...... mized, non-inferiority, trial.

@en

P2093

Charles J Woodrow

http://www.w3.org/2001/XMLSchema#string

Faizullah Kaker

http://www.w3.org/2001/XMLSchema#string

Ghulam Rahim Awab

http://www.w3.org/2001/XMLSchema#string

Sue Jean Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Therapeutic responses to different antimalarial drugs in vivax malaria

Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster

The neglected burden of Plasmodium vivax malaria

Vivax malaria: neglected and not benign

Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua.

Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia.

Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals.

Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison.

Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria.

A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of plasmodium vivax in Northwest Frontier Province, Pakistan

P2888

1475-2875-9-105

P304

105

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1475-2875-9-105

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas John White

Nicholas P J Day

Sasithon Pukrittayakamee

Pratap Singhasivanon

P577

2010-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43246487

http://www.w3.org/2001/XMLSchema#string

P6179

1015196955

http://www.w3.org/2001/XMLSchema#string

P698

20409302

http://www.w3.org/2001/XMLSchema#string

P921

Plasmodium vivax

P932

2864284

http://www.w3.org/2001/XMLSchema#string